Innovent Biologics Inc

Research Innovent Biologics Inc (6IB) on Bullrun: market cap EUR 14.31B, P/E 137.5. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker6IB
• ExchangeF
• CountryChina
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 14.31B
• P/E137.5
• Financial periodFY2025
• RevenueEUR 13.04B
• Revenue growth38.4%
• Net incomeEUR 813.57M
• Free cash flowEUR 9.32B
• Gross margin86.5%

Valuation Snapshot

latest market cap is EUR 14.31B; P/E is 137.5.

About Innovent Biologics Inc

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases.

Frequently asked questions

What is Innovent Biologics Inc's market cap?

Innovent Biologics Inc's market capitalization is EUR 14.31B.

What is Innovent Biologics Inc's P/E ratio?

Innovent Biologics Inc's price-to-earnings (P/E) ratio is 137.5.

What does Innovent Biologics Inc do?

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally.